Matthew Winton Biography and Net Worth

Before joining CervoMed, Dr. Winton served as Chief Operating Officer at Inozyme Pharma, where he oversaw commercial readiness and strategic operations, contributing to the company’s successful acquisition by BioMarin Pharmaceuticals. Previously, he spent almost a decade at Biogen, where he held senior leadership roles including Senior Vice President and Head of the U.S. Multiple Sclerosis Franchise and Vice President and Head of the U.S. Spinal Muscular Atrophy Franchise. In these roles, he built and scaled commercial organizations, managed multi-billion-dollar neurology portfolios, and guided the launch and growth of SPINRAZA™, the first approved treatment for spinal muscular atrophy (SMA). Earlier in his career, Dr. Winton advised biotechnology and pharmaceutical clients on commercialization strategy at Campbell Alliance and Leerink Swann Strategic Advisors. Dr. Winton holds a Ph.D. in Neuroscience from the Université de Montreal, an M.B.A. in Health Sector Management from Boston University, and a B.Sc. in Biology and Psychology from York University. He completed his postdoctoral fellowship at the Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania.